Galenica Sante Ag Stock Price To Sales
| GALE Stock | CHF 76.50 0.35 0.46% |
Galenica Sante AG fundamentals help investors to digest information that contributes to Galenica Sante's financial success or failures. It also enables traders to predict the movement of Galenica Stock. The fundamental analysis module provides a way to measure Galenica Sante's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Galenica Sante stock.
Galenica |
Galenica Sante AG Company Price To Sales Analysis
Galenica Sante's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Galenica Sante Price To Sales | 0.94 X |
Most of Galenica Sante's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Galenica Sante AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Galenica Sante AG has a Price To Sales of 0.942 times. This is 95.6% lower than that of the Healthcare sector and 99.04% lower than that of the Biotechnology industry. The price to sales for all Switzerland stocks is 91.75% higher than that of the company.
Galenica Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Galenica Sante's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Galenica Sante could also be used in its relative valuation, which is a method of valuing Galenica Sante by comparing valuation metrics of similar companies.Galenica Sante is currently under evaluation in price to sales category among its peers.
Galenica Fundamentals
| Return On Equity | 0.15 | |||
| Return On Asset | 0.0492 | |||
| Profit Margin | 0.04 % | |||
| Operating Margin | 0.05 % | |||
| Current Valuation | 4.26 B | |||
| Shares Outstanding | 49.64 M | |||
| Shares Owned By Insiders | 0.17 % | |||
| Shares Owned By Institutions | 49.77 % | |||
| Price To Earning | 16.37 X | |||
| Price To Book | 3.16 X | |||
| Price To Sales | 0.94 X | |||
| Revenue | 3.83 B | |||
| Gross Profit | 427.92 M | |||
| EBITDA | 305.98 M | |||
| Net Income | 167.68 M | |||
| Cash And Equivalents | 164.98 M | |||
| Cash Per Share | 2.13 X | |||
| Total Debt | 579.88 M | |||
| Debt To Equity | 43.80 % | |||
| Current Ratio | 1.77 X | |||
| Book Value Per Share | 23.35 X | |||
| Cash Flow From Operations | 333.1 M | |||
| Earnings Per Share | 3.45 X | |||
| Target Price | 70.0 | |||
| Number Of Employees | 5.52 K | |||
| Beta | 0.19 | |||
| Market Capitalization | 3.74 B | |||
| Total Asset | 2.57 B | |||
| Z Score | 4.6 | |||
| Annual Yield | 0.03 % | |||
| Net Asset | 2.57 B | |||
| Last Dividend Paid | 2.1 |
About Galenica Sante Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Galenica Sante AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Galenica Sante using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Galenica Sante AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Galenica Stock Analysis
When running Galenica Sante's price analysis, check to measure Galenica Sante's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galenica Sante is operating at the current time. Most of Galenica Sante's value examination focuses on studying past and present price action to predict the probability of Galenica Sante's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galenica Sante's price. Additionally, you may evaluate how the addition of Galenica Sante to your portfolios can decrease your overall portfolio volatility.